
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934

Filed by the Registrant
Filed by a party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material Pursuant to § 240.14a-12

DIAMEDICA THERAPEUTICS INC.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- (1) Title of each class of securities to which transaction applies:
.....
- (2) Aggregate number of securities to which transaction applies:
.....
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
.....
- (4) Proposed maximum aggregate value of transaction:
.....
- (5) Total fee paid:
.....
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
- (1) Amount Previously Paid:
.....
- (2) Form, Schedule or Registration Statement No.:
.....
- (3) Filing Party:
.....
- (4) Date Filed:
.....
-
-

***** Exercise Your *Right* to Vote *****
**Important Notice Regarding the Availability of Proxy Materials for the
Annual General and Special Shareholder Meeting to Be Held on May 22, 2019.**

DIAMEDICA THERAPEUTICS INC.



DIAMEDICA THERAPEUTICS INC.
2 CARLSON PARKWAY
SUITE 260
MINNEAPOLIS, MN 55447

Meeting Information

Meeting Type: Annual General and Special Meeting
For holders as of: March 28, 2019
Date: May 22, 2019 **Time:** 2:30 PM CDT
Location: The offices of Fox Rothschild LLP
222 South Ninth Street, Suite 2000
Minneapolis, Minnesota 55402

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

**See the reverse side of this notice to obtain
proxy materials and voting instructions.**

— **Before You Vote** —
How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT 2018 ANNUAL REPORT

How to View Online:

Have the information that is printed in the box marked by the arrow → XXXX XXXX XXXX XXXX (located on the following page) and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

- 1) BY INTERNET: www.proxyvote.com
- 2) BY TELEPHONE: 1-800-579-1639
- 3) BY E-MAIL*: sendmaterial@proxyvote.com

* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow → XXXX XXXX XXXX XXXX (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 8, 2019 to facilitate timely delivery.

— **How To Vote** —

Please Choose One of the Following Voting Methods

Vote In Person: Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow → XXXX XXXX XXXX XXXX (located on the following page) available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting Items

THE BOARD OF DIRECTORS RECOMMENDS YOU VOTE "FOR" THE FOLLOWING:

1. Election of Directors

Nominees:

- 1a. Richard Pilnik
- 1b. Michael Guffre, M.D.
- 1c. James Parsons
- 1d. Rick Pauls
- 1e. Zhenyu Xiao, Ph.D.

THE BOARD OF DIRECTORS RECOMMENDS YOU VOTE "FOR" PROPOSALS 2, 3 AND 4.

- 2. Approval of the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan.
- 3. Approval of the Continuance of DiaMedica out of the Canadian federal jurisdiction under the *Canada Business Corporations Act* and into British Columbia under the *Business Corporations Act* (British Columbia).
- 4. Appointment of Baker Tilly Virchow Krause, LLP as our Independent Registered Public Accounting Firm, and authorization to the Board of Directors to fix the auditors remuneration.

NOTE: To transact such other business as may properly come before the Annual General and Special Meeting or at any continuation, postponement or adjournment thereof.

E67215-P21538

